Insider Buying: Cooper Companies (NASDAQ:COO) Director Purchases $162,870.00 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Walter Rosebrough, Jr. bought 3,000 shares of Cooper Companies stock in a transaction on Monday, September 14th. The stock was acquired at an average cost of $54.29 per share, with a total value of $162,870.00. Following the acquisition, the director owned 20,000 shares in the company, valued at approximately $1,085,800. This represents a 17.65% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Cooper Companies Trading Down 1.5%

Shares of NASDAQ:COO opened at $53.78 on Friday. The company has a market cap of $10.23 billion, a P/E ratio of 18.35, a PEG ratio of 2.22 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The Cooper Companies, Inc. has a 1 year low of $51.01 and a 1 year high of $89.83. The stock’s fifty day moving average price is $70.23 and its 200-day moving average price is $68.77.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period last year, the company earned $0.49 EPS. Cooper Companies’s revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts expect that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its Board of Directors has initiated a share repurchase plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director Lawrence Kurzius purchased 10,000 shares for approximately $549,300, increasing his position by 47.4%. Other directors, including Paul Keel and Walter Rosebrough Jr., also recently bought shares. The purchases may provide a modest confidence signal from insiders after the selloff. Insider purchase report
• Neutral Sentiment: Jana Partners is pressing Cooper to replace its chief executive and pursue an urgent overhaul, citing “chronic underperformance.” The activist campaign could create a catalyst for strategic change, but it also increases leadership and execution uncertainty. Wall Street Journal activist report
• Negative Sentiment: Cooper’s latest quarterly results beat adjusted EPS expectations, $1.15 versus $1.12, but revenue of approximately $1.07 billion missed the $1.10 billion consensus. Management also reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 and revenue guidance to $4.23–$4.25 billion, reflecting weaker contact-lens demand.
• Negative Sentiment: Reports that U.S. distributors are reducing channel inventories have raised concerns about near-term sales and whether the weakness reflects temporary destocking or softer underlying demand. Inventory destocking report
• Negative Sentiment: Pomerantz, Bragar Eagel & Squire, and Levi & Korsinsky announced investigations into potential securities claims. These notices do not establish wrongdoing, but they add legal and headline risk. Analysts have also lowered their consensus price target to about $72.27. Pomerantz investigation

Institutional Investors Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Root Financial Partners LLC lifted its stake in shares of Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares during the period. Avalon Trust Co bought a new stake in Cooper Companies during the second quarter valued at approximately $25,000. SJS Investment Consulting Inc. grew its position in Cooper Companies by 107.5% during the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after buying an additional 187 shares during the period. Elevation Wealth Partners LLC increased its holdings in Cooper Companies by 1,136.4% during the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after buying an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC purchased a new stake in Cooper Companies during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup reissued a “neutral” rating and set a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. William Blair cut shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a report on Thursday, September 10th. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research report on Friday, June 5th. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research note on Wednesday, May 27th. Finally, JPMorgan Chase & Co. lowered their price target on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a report on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $71.47.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.